Breaking News Instant updates and real-time market news.

CNST

Constellation Pharmaceuticals

$5.78

-0.225 (-3.75%)

16:50
12/10/18
12/10
16:50
12/10/18
16:50

Constellation Pharmaceuticals initiates Phase 2 portion of ProSTAR trial

Constellation Pharmaceuticals announced an update of the ProSTAR study, its ongoing Phase 1b/2 clinical trial of CPI-1205 in patients with metastatic castration-resistant prostate cancer. The ProSTAR study is evaluating CPI-1205, Constellation's potent and highly selective small-molecule EZH2 inhibitor, in combination with either enzalutamide or abiraterone / prednisone, in mCRPC patients who experienced disease progression while receiving the other ARS inhibitor. Based on encouraging results from the Phase 1b portion of ProSTAR, the Company has initiated dosing in the randomized Phase 2 portion studying CPI-1205 in combination with enzalutamide versus enzalutamide alone. Constellation has also decided to expand the Phase 2 portion of the study by adding an arm evaluating CPI-1205 in combination with abiraterone in the second-line setting. "We are pleased that CPI-1205 achieved its Phase 1b endpoints in ProSTAR, demonstrating an encouraging safety profile and evidence of clinical activity in both arms," said Adrian Senderowicz, Chief Medical Officer of Constellation Pharmaceuticals. "As we advance into the Phase 2 portion of the study, we believe combination therapy with CPI-1205 may provide a meaningful second-line treatment option to patients with metastatic castration-resistant prostate cancer, an area of significant unmet medical need. We are excited about expanding our opportunity to include an arm evaluating CPI-1205 in combination with abiraterone in the second-line setting, given that very few patients experience a 50% reduction in PSAs on second-line treatment with abiraterone and that time to progression in this setting is typically short."

  • 12

    Dec

CNST Constellation Pharmaceuticals
$5.78

-0.225 (-3.75%)

08/13/18
08/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Crinetics (CRNX) was initiated with an Outperform at Leerink, an Overweight at Piper Jaffray, and a Neutral at JPMorgan. 2. Hasbro (HAS) was initiated with an Overweight at Consumer Edge while Mattel (MAT) initiated with an Equal Weight. 3. Allakos (ALLK) initiated with an Outperform at William Blair, a Buy at Jefferies, and a Neutral at Goldman Sachs. 4. Constellation Pharmaceuticals (CNST) was initiated with an Overweight at JPMorgan as well as an Outperform at BMO Capital and Oppenheimer. 5. Rubius Therapeutics (RUBY) initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/18
JPMS
08/13/18
INITIATION
Target $17
JPMS
Overweight
Constellation Pharmaceuticals initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Constellation Pharmaceuticals with an Overweight rating and $17 price target. The 35% selloff since the initial public offering is overdone and creates an "interesting/compelling entry point ahead of more robust proof-of-concept data" for both CPI-1205/CPI-0610 in mid-2019, Rama tells investors in a research note.
08/13/18
BMOC
08/13/18
INITIATION
Target $19
BMOC
Outperform
Constellation Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Constellation Pharmaceuticals with an Outperform rating and a price target of $19, saying that while the stock reflects its lead asset CPI-1205, the valuation for its second drug - CPI-0610, a BET inhibitor, for myelofibrosis - is "minimal". The analyst notes that his price target accounts for accounts for risk-adjusted revenues for both programs, but the upside scenario could produce $35 per share price as expects CPI-1205 to show synergistic benefit with Xtandi/Zytiga in castration-resistant prostate cancer and for CPI-0610 to potentially "expand Jakafi's $1B market by improving response rates and increasing treatment duration".
08/13/18
OPCO
08/13/18
INITIATION
Target $21
OPCO
Outperform
Constellation Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Constellation Pharmaceuticals with an Outperform rating and $21 price target. The analyst models CPI-1205 to launch in 2023 in prostate cancer and CPI-0610 to launch in 2023 in myelofibrosis. CPI-1205 could result in 2025 product sales of $1.84B, and CPI-0610 could generate 2025 product sales of $249.2M, Rush Cann tells investors i a research note.

TODAY'S FREE FLY STORIES

LNT

Alliant Energy

$52.60

0.9 (1.74%)

06:34
11/14/19
11/14
06:34
11/14/19
06:34
Syndicate
Alliant Energy files to sell $195.6M in common stock »

Barclays Capital Inc. is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PXS

Pyxis Tankers

$1.01

-0.08 (-7.34%)

06:34
11/14/19
11/14
06:34
11/14/19
06:34
Earnings
Pyxis Tankers reports Q3 EPS (4c), consensus (4c) »

Reports Q3 revenue $7.3M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FB

Facebook

$193.20

-1.27 (-0.65%)

06:33
11/14/19
11/14
06:33
11/14/19
06:33
Periodicals
Facebook looked to buy Musical.ly in 2016, BuzzFeed News reports »

Facebook spent the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REPL

Replimune Group

$13.55

-3.3 (-19.58%)

06:33
11/14/19
11/14
06:33
11/14/19
06:33
Syndicate
Replimune Group 3.678M share Secondary priced at $13.61 »

The deal size was reduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CERC

Cerecor

$3.28

-0.07 (-2.09%)

06:32
11/14/19
11/14
06:32
11/14/19
06:32
Earnings
Cerecor reports Q3 EPS (7c), consensus (13c) »

Reports Q3 revenue $5.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$42.94

-0.05 (-0.12%)

06:30
11/14/19
11/14
06:30
11/14/19
06:30
Earnings
GDS Holdings reports Q3 EPS (12c), consensus (8c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 09

    Dec

AAPL

Apple

$264.52

2.63 (1.00%)

06:30
11/14/19
11/14
06:30
11/14/19
06:30
Periodicals
Apple Watch detects irregular heartbeats in study, Reuters reports »

Apple's Heart study,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALB

Albemarle

$65.25

-0.03 (-0.05%)

06:30
11/14/19
11/14
06:30
11/14/19
06:30
Downgrade
Albemarle rating change  »

Albemarle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 12

    Dec

BABA

Alibaba

$182.48

-4.49 (-2.40%)

06:27
11/14/19
11/14
06:27
11/14/19
06:27
Periodicals
Alibaba to carry out Hong Kong's first paperless listing, Reuters reports »

Alibaba will carry out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BA

Boeing

$362.42

-0.47 (-0.13%)

06:24
11/14/19
11/14
06:24
11/14/19
06:24
Periodicals
Boeing drops automation system used to build 777 jets, Bloomberg reports »

Boeing is abandoning a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PING

Ping Identity

$16.50

-0.25 (-1.49%)

06:23
11/14/19
11/14
06:23
11/14/19
06:23
Recommendations
Ping Identity analyst commentary  »

Ping Identity beat on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

DDAIF

Daimler AG

$0.00

(0.00%)

06:20
11/14/19
11/14
06:20
11/14/19
06:20
Hot Stocks
Breaking Hot Stocks news story on Daimler AG »

Daimler Chairman:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$242.37

3.04 (1.27%)

06:20
11/14/19
11/14
06:20
11/14/19
06:20
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

06:20
11/14/19
11/14
06:20
11/14/19
06:20
Hot Stocks
Daimler says Daimler Mobility sees ROE of over 12% in 2020 »

Mercedes-Benz Trucks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

06:19
11/14/19
11/14
06:19
11/14/19
06:19
Hot Stocks
Daimler seeks EUR1B in savings at Mercedes-Benz by cutting jobs »

Daimler presented a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:16
11/14/19
11/14
06:16
11/14/19
06:16
Recommendations
Cisco analyst commentary  »

Cisco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

UBS

UBS

$12.16

-0.17 (-1.38%)

06:15
11/14/19
11/14
06:15
11/14/19
06:15
Hot Stocks
UBS fined SGD$11.2M over deceptive bond trades »

The Monetary Authority of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CYDY

CytoDyn

$0.00

(0.00%)

06:15
11/14/19
11/14
06:15
11/14/19
06:15
Hot Stocks
CytoDyn names Craig Eastwood as CFO »

CytoDyn announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPE

Callon Petroleum

$4.47

-0.175 (-3.77%)

, CRZO

Carrizo Oil & Gas

$7.73

-0.21 (-2.64%)

06:13
11/14/19
11/14
06:13
11/14/19
06:13
Hot Stocks
Callon Petroleum, Carrizo Oil & Gas announce amendment to merger agreement »

Callon Petroleum (CPE)…

CPE

Callon Petroleum

$4.47

-0.175 (-3.77%)

CRZO

Carrizo Oil & Gas

$7.73

-0.21 (-2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

GECC

Great Elm Capital

$8.23

-0.02 (-0.24%)

06:13
11/14/19
11/14
06:13
11/14/19
06:13
Earnings
Great Elm Capital reports Q3 NII 26c, consensus 25c »

Net assets on September…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CSCO

Cisco

$48.44

0.06 (0.12%)

, SANM

Sanmina

$32.76

0.26 (0.80%)

06:13
11/14/19
11/14
06:13
11/14/19
06:13
Recommendations
Cisco, Sanmina, Flex, Jabil analyst commentary  »

Cisco results negative…

CSCO

Cisco

$48.44

0.06 (0.12%)

SANM

Sanmina

$32.76

0.26 (0.80%)

FLEX

Flex

$12.33

0.39 (3.27%)

JBL

Jabil

$39.27

0.28 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

BCLI

BrainStorm

$3.88

0.05 (1.31%)

06:12
11/14/19
11/14
06:12
11/14/19
06:12
Earnings
BrainStorm reports Q3 EPS (25c), consensus (22c) »

"On October 11, 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 11

    Dec

RMBL

RumbleON

$1.50

-0.83 (-35.62%)

06:11
11/14/19
11/14
06:11
11/14/19
06:11
Recommendations
RumbleON analyst commentary  »

RumbleON price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AXNX

Axonics

$25.49

0.53 (2.12%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Hot Stocks
Axonics announces FDA approval of Axonics r-SNM System »

Axonics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

EPAM

Epam Systems

$200.74

0.85 (0.43%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.